Efficacy and Safety of Aripiprazole in the Treatment of Schizophrenia: a Randomized, Double-Blind, Risperidone Controlled, Multicenter Study
闫俊,张鸿燕,舒良,李华芳,顾牛范,王刚,蔡焯基,肖卫东,王高华,谢世平,张心保,李婷,马崔,姚晨
DOI: https://doi.org/10.3321/j.issn:1006-7884.2008.02.005
2008-01-01
Abstract:Objective To evaluate the efficacy and safety of aripiprazole in treatment of patientswith acute exacerbation of schizophrenia.Methods A randomized,double-blind,multi-center,controlled clinical trim was conducted.All subjects(n=240)received 6 weeks treatment with either aripiprazole(n=120)or fispefidone(n=120),with the dosage of 10-30 mg/d and 2-6 ms/d respectively.The main efficacy measure was the change in total score of the PANSS and response rate.Results The mean reduction score of PANSS were 32.86 in aripiprazole and 36.58 in risperidone at the endpoint of treatment,and the clinical response rates were 64.3%and 68.9%respectively.There were no significant differences between both groups(F=1.61,P=0.206)(x2=1.00,P=0.316).The incidence of adverse events was approximate in both the groups,with lower liability for weight gain and effects on serum prolactin level in aripiprazole than in fispefidone treatment(F=4.535,P=0.034;F=33.576,P=0.000).Conclusion The resuhs show that aripiprazole has similar therapeutic effect to risperidone in treatment of patients with acute exacerbation of schizophrenia.Aripiprazole is safe and well tolerated in Chinese population.